BioCentury | Jul 31, 2020

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 24, 2020

Olema aims to deploy $54M round to carve its niche in breast cancer

Olema’s plans for its oral selective estrogen receptor degrader attracted a crossover-laden syndicate to the San Francisco company’s $54 million series B round. Olema plans to take the therapy, which is administered daily, into a...
BioCentury | Jul 23, 2020

EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs

The first disclosed deals for Alexis Borisy’s EQRx provide a glimpse of the targets and economics of its low-cost approach to drug development. The company, which launched in January with $200 million, is using a...
BioCentury | Jul 17, 2020

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition...
BioCentury | Jun 26, 2020
Distillery Therapeutics

CDK12 identified as myotonic dystrophy target

DISEASE CATEGORY: Musculoskeletal INDICATION: Myotonic dystrophy type 1 (DM1) Inhibiting the transcription elongation regulator CDK12 could treat DM1, which is caused by CTG repeat expansions in the DMPK gene that result in cellular accumulation of...
BioCentury | Jun 23, 2020
Distillery Therapeutics

CDKL5 identified as target in acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Inhibiting the kinase CDKL5 could treat acute kidney injury (AKI). In kinome-wide siRNA screens in human and mouse renal tubular epithelial cells, CDKL5 was the gene for which knockdown...
BioCentury | Jun 17, 2020
Product Development

Data in early breast cancer recurrence point to larger market for Lilly’s Verzenio

The positive Phase III readout of Lilly’s Verzenio in early breast cancer opens a path to a new market for the CDK4 and CDK6 inhibitor, one that was recently made clearer by the failure of...
BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting AFF4 and CDK9, components of the transcription-regulating super elongation complex, could treat diffuse midline glioma. In human diffuse midline glioma cell lines, shRNAs targeting AFF4 or CDK9 or...
Items per page:
1 - 10 of 636